Global NGS Oncology Market to Reach $51.78 Billion by 2032 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "NGS Oncology Market - A Global and Regional Analysis: Focus on Offering, Sequencing Technology, Workflow, Application, End User, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Global NGS Oncology Market Industry Overview

The global NGS oncology market is projected to reach $51,783.0 million in 2032 from 14,828.6 million in 2021, witnessing a CAGR of 12.04% during the forecast period 2022-2032. The growth in the NGS oncology market is expected to be driven by an increasing number of panels or kits, bioinformatics services for computational analysis, and a rising number of open-source free sequencing platform providers offering NGS oncology.

Market Segmentation

by Sequencing Technology

• Targeted Sequencing
• Genomics
• Transcriptomics
• Epigenomics

by Offering

• Platform
• Kits
• Services

by Workflow

• Pre-Sequencing
• Sequencing
• Data Analysis

by Application

• Genetic Screening
• Hereditary Genetic Testing
• Hematological Malignancies
• Solid Tumors
• Other Applications

by End User

• Hospitals and Clinics
• Clinical Research Organizations (CROs)
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Other End Users

Demand - Drivers and Limitations

Following are the demand drivers for the global NGS Oncology Market:

• Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques
• Reducing Cost of Sequencing
• Rapid Technological Advancements Related to NGS Oncology

The market is expected to face some limitations too due to the following challenges:

• Inadequate NGS Oncology Reimbursement Scenario
• Increasing Cost of NGS Automated Sample Preparation Instruments
• Barriers in the Advancement of NGS Oncology

Key Market Players and Competition Synopsis

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Biodesix, Inc.
• Caris Life Sciences
• DNASTAR
• Fulgent Genetics, Inc.
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Invitae Corporation
• IntegraGen (OncoDNA)
• Oxford Nanopore Technologies plc.
• Pacific Biosciences of California, Inc.
• PerkinElmer, Inc.
• Pillar Biosciences, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Takara Bio Inc.
• Vela Diagnostics

For more information about this report visit https://www.researchandmarkets.com/r/37tz0s

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900